Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Aprimorando a tomada de decisão compartilhada para orientar o cuidado de pessoas com demência e diabetes (CGM ASSIST)

2 de outubro de 2026 atualizado por: April Savoy, Indiana University

Aprimorando a tomada de decisão compartilhada para orientar e orientar o atendimento individualizado para pessoas com doença de Alzheimer e diabetes

The goal of this study is to test CGM ASSIST. This is a digital tool that uses an interactive information display-an easy-to-read screen designed to help people with dementia (or memory loss) and diabetes, as well as their caregivers and doctors.

Managing diabetes is often difficult for people with memory issues. This study uses a Continuous Glucose Monitor (CGM), which is a device that tracks blood sugar levels in real-time. CGM ASSIST adds a new way to see this data through interactive displays. These displays show clear information and medical guidelines to help patients and caregivers make sense of the glucose readings.

The study aims to:

  • Increase Awareness: Help patients and caregivers recognize the dangers of low blood sugar (hypoglycemia) and how to treat it.
  • Improve Teamwork: Encourage "shared decision-making," where patients, caregivers, and doctors work together to make health choices.
  • Test Feasibility: See if it is easy and helpful for people with memory loss to use these interactive displays in their daily lives.
  • Understand Experiences: Learn how the thoughts and feelings of patients and families affect how they manage diabetes.

By using these interactive displays, the researchers hope to make it easier for families to understand their health needs and communicate better with their medical team.

Participants will:

  • Answer a survey about how they manage their diabetes
  • Learn how to use a Continuous Glucose Monitor and wear it for 14 days
  • Answer 3 brief telephone surveys during these 14 days
  • Complete a clinic visit with their doctor and answer a final survey on how this visit went using the CGM ASSIST report

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Background and Clinical Significance Over 11 million Americans aged 65 and older live with diabetes mellitus (DM), and an estimated 13-20% of this population also has Alzheimer's disease and related dementias (ADRD). Hypoglycemia is a serious and frequent complication in this population, affecting 10-25% of patients and increasing the risk of coma, macrovascular events, and death.

A harmful cycle exists in ADRD-DM management: cognitive impairment hinders the detection of hypoglycemia and the management of glucose levels, while low glucose levels further impair cognition. Although clinical guidelines recommend de-intensifying medications and simplifying routines to reduce risk, these guidelines are often not implemented in clinical practice.

The Role of Continuous Glucose Monitoring (CGM) Continuous glucose monitoring (CGM) devices are effective tools for detecting hypoglycemia by tracking glucose levels every 5-15 minutes. While CGM has proven feasible in older adults without cognitive impairment, research indicates that standard CGM data reports are often difficult for patients and caregivers to interpret. This lack of interpretability creates a barrier to shared decision-making regarding behavior modifications, glycemic targets, and medication de-intensification.

Study Objective: CGM ASSIST This study aims to address these translational gaps by developing and testing CGM ASSIST. This intervention adapts standard CGM technology by adding interactive information displays (novel companion information guides) designed specifically for the ADRD-DM population and their caregivers.

The study follows a multi-phase approach:

Characterization of Needs: Identifying the unmet needs and decision-making processes of patient-caregiver dyads using CGM.

User-Centered Design: Engaging patients, caregivers, and clinicians in a design process to create the CGM ASSIST interactive reports.

Pilot Testing: Conducting a clinical trial to assess the feasibility, usability, and impact of the CGM ASSIST reports on shared decision-making and individualized care.

The long-term goal of this research is to improve the characterization of decision-making in adults with MCI and ADRD and to provide tools that help families identify and address unmet medical needs through better interpretation of clinical data.

Tipo de estudo

Intervencional

Inscrição (Estimado)

62

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: April Savoy, PhD
  • Número de telefone: 317-278-2194
  • E-mail: asavoy@iu.edu

Estude backup de contato

Locais de estudo

    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Recrutamento
        • Eskenazi Health
        • Contato:
          • Patricia Noblet

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

65 anos e mais velhos (Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Patient-Caregiver Dyad Inclusion Criteria:

  • patient must have dual diagnosis of MCI or ADRD and diabetes (DM)
  • patient must have active prescriptions for DM
  • patient must have had at least one visit to an Eskenazi or IU Health primary care clinic within 12 months
  • patient must be able to provide assent and have a legally authorized representative (LAR) consent on their behalf if patient lacks capacity to consent
  • patient must have a caregiver aged 18 years or older who interacts daily, or almost daily, with the patient
  • patient and caregiver must both speak English
  • patient and caregiver must both reside in the community
  • dyad must have internet access

Patient-Caregiver Dyad Exclusion Criteria:

  • patient has terminal illness
  • use of an automated insulin delivery system
  • patient is receiving dialysis
  • patient is taking ascorbic acid during monitoring period
  • patient has existing implanted medical devices
  • patient has a bleeding disorder
  • patient has a pre-existing arm skin lesions
  • patient has an allergy to medical adhesive or isopropyl alcohol
  • patient has plans for imaging or diathermy treatment during the study period

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Pesquisa de serviços de saúde
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Patient-Caregiver Dyads

Participants will wear a continuous glucose monitor

CGM education and glucose data collection for 14 days with a device. Interviews with dyads to assess experience and awareness of hypoglycemic events.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Feasibility- Recruitment
Prazo: 8 months

Total number of participants enrolled divided by the total participants screened as eligible.

8 months
Feasibility- Retention
Prazo: 2 months

Total number of participants who completed the study divided by the total number of participants enrolled in the study.

2 months
Feasibility- CGM Device Adherence
Prazo: 14 days

This measures data completeness. Total number of days CGM worn and active divided by the total number of days in the observation period.

14 days
System Usability Scale
Prazo: 2 months

The System Usability Scale (SUS) is a 10-item validated questionnaire used to evaluate the usability of the CGM ASSIST interactive information display. Participants rate each item on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree). To calculate the final SUS score, the response for each odd-numbered item is reduced by 1, and the response for each even-numbered item is subtracted from 5. These adjusted scores are then summed and multiplied by 2.5. The total score ranges from 0 to 100. A higher score indicates better usability (e.g., a score above 68 is generally considered above average).

2 months
CollaboRATE Questionnaire
Prazo: 2 months

The CollaboRATE questionnaire is a 3-item validated patient-reported measure used to assess the level of shared decision-making during clinical encounters. The three items focus on how much effort was made: 1) to help the participant understand their health issues, 2) to listen to what matters most to the participant, and 3) to include the participant's preferences in the choice of next steps. Each item is scored on a 5-point Likert scale ranging from 1 (No effort was made) to 5 (Every effort was made). For each participant, a total score is calculated by summing the scores of the three items. The total score ranges from 3 to 15. A higher score indicates a higher perceived level of shared decision-making.

2 months
Number of Changes in Diabetes Management
Prazo: 12 months

This measure tracks the total number of management changes made to a participant's diabetes care plan based on medical record review. A "change" is defined as any of the following: 1) Initiation of new medications or technology, 2) New referrals to specialists or community services, 3) Discontinuation of existing medications, and 4) Modification (increase or decrease) of current medication dosages.

12 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Hypoglycemia - Time Below Range (TBR)
Prazo: 14 days

The percentage of time the participant spent with glucose levels below the target range. Percentage = glucose readings and time 54-69 mg/dL / total amount of readings and time monitored [CGM performs calculation]. This includes Level 1 hypoglycemia (54-69 mg/dL) and Level 2 hypoglycemia (<54 mg/dL).

14 days
Glucose Level - Time In Range (TIR)
Prazo: 14 days

Percentage of time the participant spent within the target glucose range of 70-180 mg/dL. Percentage = glucose readings and time 70-180 mg/dL / total amount of readings and time monitored [CGM performs calculation].

14 days
Glucose Management Indicator (GMI)
Prazo: 14 days

Estimated HbA1c percentage based on the average glucose levels captured by the CGM. Automated calculation based on 14 days of CGM data [CGM performs calculation]

14 days
Glucose Variability (%GV)
Prazo: 14 days

Oscillations in blood glucose levels: Measurement of fluctuations of glucose or other related parameters of glucose homoeostasis over a given interval of time (i.e., within a day, between days or longer term). Calculation as the coefficient of variation (%CV). The goal for stable glycemic control is a variability of ≤36% [CGM performs calculation]

14 days
Mean Glucose Level
Prazo: 14 days

This mean is calculated by taking the total sum of glucose averages divided by the total number of days of glucose readings [CGM performs calculation].

14 days

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: April Savoy, PhD, Indiana University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

29 de setembro de 2026

Conclusão Primária (Estimado)

30 de junho de 2027

Conclusão do estudo (Estimado)

30 de junho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

11 de novembro de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de dezembro de 2022

Primeira postagem (Real)

8 de dezembro de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de outubro de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 13925
  • 1K01AG076971 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .